Risk of endophthalmitis remains low

Intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents have not only changed how neovascular age-related macular degeneration (AMD) is managed, but its expanded indications are impacting the management of retinal vascular occlusion, neovascular glaucoma, and diabetic macular edema. Here the authors describe risk factors and outcomes associated with the most feared complication of these intravitreal injections, endophthalmitis.
Source: Optometry